英国批准新的"铁马"癌症治疗 给血癌患者带来希望 New "Trojan horse" cancer treatment approved in England, offering hope to blood cancer patients.

英国的血癌患者将是世界上第一批接受新的“Trojan马”治疗的“Belantamab mafodotin”(Blenrep)的患者之一。 Blood cancer patients in England will be among the first in the world to receive a new "Trojan horse" treatment, belantamab mafodotin (Blenrep), after it was approved by the National Institute for Health and Care Excellence (Nice) for NHS use. GlaxoSmithKline提供的定向治疗可以阻止近三倍于现有治疗的骨髓瘤发育。 The targeted therapy, made by GlaxoSmithKline, can stop myeloma from progressing nearly three times longer than existing treatments. 作为每三周一次的注入, 药物的作用是进入癌症细胞, 释放致命分子从内部摧毁它们。 Given as an infusion every three weeks, the drug works by entering cancer cells and releasing a lethal molecule to destroy them from the inside. 预计这种创新治疗将为数千名患者带来希望。 This innovative treatment is expected to offer hope to thousands of patients.